Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UX016 in Adults With GNE Myopathy
NCT07511556Phase 2Recruiting
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of UX016 in GNE myopathy (HIBM), sponsored by Ultragenyx Pharmaceutical Inc.. Started Oct 2026; status: recruiting.
02
Drugs
UX016
03
Conditions
GNE myopathy (HIBM)
Beyond the preview
Go deeper on NCT07511556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07511556.